Eli Lilly has released results from its phase 3 TRIUMPH-1 trial, revealing that the experimental weight-loss drug retatrutide led to significant body weight reductions in adults with obesity or overweight. Participants receiving the 12 mg dose lost an average of 28.3% of their body weight over 80 weeks, according to data released by the company.
A Triple-Action Mechanism for Weight Management
Retatrutide represents a new class of weight-loss medication that functions by targeting three distinct hormonal receptors simultaneously: GLP-1, GIP, and glucagon. While current market leaders like Wegovy operate primarily on the GLP-1 receptor and Mounjaro targets both GLP-1 and GIP, the addition of the glucagon receptor activity distinguishes retatrutide in its pharmacological approach, as reported by Maariv.
The TRIUMPH-1 trial included 2,339 adults who were categorized as having obesity or overweight with at least one weight-related medical condition, excluding diabetes. Participants were randomized into four groups to receive either a placebo or weekly injections of retatrutide at 4 mg, 9 mg, or 12 mg doses. The treatment involved a gradual escalation of the dosage over the course of the 80-week primary study period, which lasted approximately one and a half years.
Clinical Outcomes and Weight Loss Milestones
The efficacy data from the trial, as covered by Emess, highlights performance metrics that rival those previously seen only in bariatric surgery. Among those who received the highest dose of 12 mg, 45.3% of participants achieved a weight loss of at least 30% of their body weight within 80 weeks. Furthermore, 27.2% of the participants in this dosage group shed more than 35% of their body weight.
- 12 mg dose: Average loss of 31.9 kg (28.3% of body weight)
- 9 mg dose: Average loss of 29.2 kg (25.9% of body weight)
- 4 mg dose: Average loss of 21.4 kg (19% of body weight)
- Placebo group: Average loss of 2.5 kg
For a specific cohort of 532 participants who began the study with a body mass index (BMI) of 35 or higher and continued treatment for up to 104 weeks—roughly two years—the results were even more substantial. Those in the high-dose extension arm experienced an average weight reduction of 30.3% of their body weight, or approximately 34 kg, according to reporting by Israel Hayom.
The study design utilized rigorous inclusion criteria to isolate the drug’s effect on weight management. Participants were required to have a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related complication—such as hypertension, dyslipidemia, or obstructive sleep apnea. By excluding patients with type 2 diabetes, the researchers aimed to provide a clearer profile of the drug’s efficacy specifically for chronic weight management in a non-diabetic population.
The metabolic impact extended beyond total weight reduction. Investigators documented improvements in cardiometabolic markers that are often secondary targets in obesity treatment. Data from the trial indicated that participants experienced statistically significant reductions in systolic and diastolic blood pressure. Furthermore, improvements in lipid profiles were noted, specifically regarding low-density lipoprotein (LDL) cholesterol and triglyceride levels. These findings are critical for determining the long-term clinical utility of retatrutide, as weight loss alone is often assessed alongside improvements in overall cardiovascular risk profiles.
Safety Profile and Regulatory Outlook
While the weight loss results are significant, the clinical trial also tracked the safety and tolerability of the drug. Consistent with other therapies in this class, the most frequently reported adverse events involved the gastrointestinal system, including nausea, vomiting, diarrhea, and constipation. The rate of treatment discontinuation due to these side effects was 11.3% in the 12 mg group, compared to 4.9% among those receiving the placebo.
Beyond body mass reduction, researchers noted secondary health improvements, including decreases in waist circumference, blood lipid levels, blood pressure, and markers of inflammation like CRP. Eli Lilly has indicated that these findings are part of a broader series of trials and that they intend to move forward toward regulatory submissions, pending the completion of remaining trial requirements and long-term safety assessments.
The side effect profile, while generally categorized as mild to moderate in severity, remains a focal point for regulatory review. The gastrointestinal symptoms were most prevalent during the dose-escalation phase of the trial, during which participants moved from lower starting doses to their assigned maintenance levels. Investigators noted that the titration schedule was designed to mitigate these effects, yet the discontinuation rates among the highest-dose cohort highlight the challenges patients may face in maintaining long-term adherence.
The company has emphasized that the 80-week data provides a robust foundation for evaluating the drug’s therapeutic index. As the pharmaceutical industry continues to monitor the triple-agonist class, the data from TRIUMPH-1 serves as a benchmark for efficacy against established GLP-1/GIP receptor agonists. Regulatory bodies will likely require additional data regarding long-term cardiovascular outcomes and potential rare side effects before considering approval for widespread clinical use.
As the drug is currently experimental and has not yet received regulatory approval for public use, patients interested in the potential of such therapies should consult their healthcare provider for guidance on existing, approved treatment options and clinical trial availability.
